Azobenzene Photoswitch for Isomerization-Dependent Cancer Therapy via Azo-Combretastatin A4 and Phototrexate

Photochem Photobiol. 2020 Nov;96(6):1163-1168. doi: 10.1111/php.13292. Epub 2020 Jul 6.

Abstract

The adverse effects of chemotherapeutic drugs to healthy organs/cells greatly limit their clinical efficacy and patient compliance. The unique behavior of azobenzene photoswitch offers a remarkable tool to address the side effects of chemotherapeutic drugs. The azobenzene moiety has been integrated within some chemotherapeutic drugs to realize photo-triggered activation of drug cytotoxicity. However, the clinical translation of these agents has been facing a few barriers. In this short review, we present our viewpoints on potential solutions to address the following challenges associated with azobenzene-based photoswitchable chemotherapeutic drugs, including poor tissue penetration of light, hypoxia-induced drug degradation in solid tumor and the autonomous cis-trans relaxation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Azo Compounds / chemistry*
  • Humans
  • Isomerism
  • Neoplasms / drug therapy*
  • Stilbenes / chemistry
  • Stilbenes / therapeutic use*

Substances

  • Antineoplastic Agents
  • Azo Compounds
  • Stilbenes
  • azobenzene
  • fosbretabulin